Price$14.03+0.70 (+5.21%)
01:30 PM07:45 PM
News · 26 weeks57-87%
2025-12-142026-06-07
Mix2090d
- SEC Filings8(40%)
- Other7(35%)
- Earnings2(10%)
- Insider1(5%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- ANALYSTErasca upgraded by BofA Securities with a new price targetBofA Securities upgraded Erasca from Underperform to Neutral and set a new price target of $16.00
- PRErasca to Present at the Jefferies Global Healthcare ConferenceSAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcas
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)
- SECSEC Form SCHEDULE 13G filed by Erasca Inc.SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)
- SECSEC Form 10-Q filed by Erasca Inc.10-Q - Erasca, Inc. (0001761918) (Filer)
- SECErasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Erasca, Inc. (0001761918) (Filer)
- PRErasca Reports First Quarter 2026 Business Updates and Financial ResultsRobust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028 SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an
- PRErasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Merck, known as MSD outside of the United States and Canada. This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with RAS-mutant (RASm) solid tumors. Erasca is sponsoring the study, and Merck is supplyi
- PRErasca to Present at the Bank of America Securities Health Care ConferenceSAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 pm Pacific Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days fol
- SECSEC Form DEFA14A filed by Erasca Inc.DEFA14A - Erasca, Inc. (0001761918) (Filer)
- SECSEC Form DEF 14A filed by Erasca Inc.DEF 14A - Erasca, Inc. (0001761918) (Filer)
- SECSEC Form 8-K filed by Erasca Inc.8-K - Erasca, Inc. (0001761918) (Filer)
- PRErasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid TumorsRobust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs Preliminary data suggest ERAS-0015 may combine safely with standard-of-care doses of panitumumab with no DLTs as of DCO (N=3) and 1/1 uPR in CRC Well-behaved PK, with dose-dependent increase in PK exposure up to MAD of 40 mg QD and no exposure plate
- SECErasca Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Erasca, Inc. (0001761918) (Filer)
- PRErasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET. Conference Call and Webcast InformationErasca will hold a conference call and webcast Monday, April 27, 2026, at 4:30 pm ET. The webcast link for the conference call is her
- SECErasca Inc. filed SEC Form 8-K: Other Events8-K - Erasca, Inc. (0001761918) (Filer)
- INSIDERSEC Form 4 filed by Garner Ebun4 - Erasca, Inc. (0001761918) (Issuer)
- SECSEC Form 144 filed by Erasca Inc.144 - Erasca, Inc. (0001761918) (Subject)
- SECSEC Form 10-K filed by Erasca Inc.10-K - Erasca, Inc. (0001761918) (Filer)
- SECErasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Erasca, Inc. (0001761918) (Filer)
- PRErasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial ResultsEncouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
- PRErasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and MacauWorldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will
- INSIDERChief Medical Officer Morris Shannon exercised 20,000 shares at a strike of $1.70 and sold $300,760 worth of shares (20,000 units at $15.04) (SEC Form 4)4 - Erasca, Inc. (0001761918) (Issuer)
ERAS FAQ
6 questionsWhere does ERAS stock trade?
Erasca Inc. (ERAS) is listed on NASDAQ.What sector and industry is ERAS in?
Erasca Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Erasca Inc. go public?
Erasca Inc. (ERAS) completed its IPO in 2021.What are analysts saying about ERAS?
Erasca Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Neutral with a $1600.00 price target on 2026-06-04.What companies are similar to ERAS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ERAS side-by-side with any of them on Quantisnow.How can I track ERAS on Quantisnow?
Quantisnow aggregates Erasca Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ERAS to receive live email and push alerts on every new disclosure.